Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 7/20 | 0.48 |
| ▸ | HTR2C | P28335 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697256 | 0.89 | SMN1; SMN2 (0.58) | L3MBTL1GAASMN1; SMN2MAPTKMT2A | |
| SCHEMBL2984058 | 0.88 | SMN1; SMN2 (0.49) | L3MBTL1GAASMN1; SMN2MAPTKMT2A | |
| SCHEMBL671244 | 0.73 | SMN1; SMN2 (0.69) | L3MBTL1GAASMN1; SMN2MAPTKMT2A | |
| SCHEMBL2985529 | 0.73 | ALDH1A1 (0.72) | GAASMN1; SMN2IKBKBCHUKKMT2A | |
| SCHEMBL2986429 | 0.71 | L3MBTL1 (0.45) | L3MBTL1GAASMN1; SMN2MAPTIKBKB | |
| SCHEMBL15258832 | 0.69 | ALDH1A1 (0.52) | L3MBTL1GAASMN1; SMN2MAPTKMT2A | |
| SCHEMBL2982114 | 0.69 | IKBKB (0.64) | L3MBTL1GAAIKBKBCHUKHTR2A | |
| SCHEMBL2991766 | 0.68 | ALDH1A1 (0.65) | GAAIKBKBCHUKKMT2AALDH1A1 | |
| SCHEMBL6701096 | 0.68 | SMN1; SMN2 (0.61) | L3MBTL1GAASMN1; SMN2MAPTKMT2A | |
| SCHEMBL12077838 | 0.68 | MAPT (0.73) | L3MBTL1GAASMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | L3MBTL1 4866/4885GAA 2061/4885SMN1; SMN2 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.